AROLDI, ANDREA

AROLDI, ANDREA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 22 (tempo di esecuzione: 0.065 secondi).
Titolo Tipologia Data di pubblicazione Autori File
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 01 - Articolo su rivista 2024 Crespiatico I.Mastini C.D'Aliberti D.Mauri M.Mercado C. M.Fontana D.Spinelli S.Crippa V.Inzoli E.Manghisi B.Civettini I.Ramazzotti D.Sangiorgio V.Brambilla V.Aroldi A.Barone C.Orsenigo R.Serafini M.Mottadelli F.Cazzaniga G.Pagni F.Azzoni E.Gambacorti Passerini C.Elli E. M.Mologni L.Piazza R. +
Idiopathic erythrocytosis: a germline disease? 01 - Articolo su rivista 2024 Elli, E. M.Mauri, M.D’Aliberti, D.Crespiatico, I.Fontana, D.Redaelli, S.Pelucchi, S.Spinelli, S.Manghisi, B.Cavalca, F.Aroldi, A.Ripamonti, A.Palamini, S.Mottadelli, F.Massimino, L.Ramazzotti, D.Cazzaniga, G.Piperno, A.Gambacorti-Passerini, C.Piazza, R. +
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 01 - Articolo su rivista 2023 Rindone, GiovanniAroldi, AndreaBossi, ElisaVerga, LuisaZambrotta, GiovanniTarantino, SaraPiazza, RoccoGambacorti-Passerini, Carlo +
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 01 - Articolo su rivista 2023 Aroldi, AndreaAngaroni, FabrizioD’Aliberti, DeborahSpinelli, SilviaCrespiatico, IlariaCrippa, ValentinaPiazza, RoccoGraudenzi, AlexRamazzotti, Daniele
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 01 - Articolo su rivista 2023 Aroldi, AMauri, MRamazzotti, DVilla, MMalighetti, FCrippa, VCocito, FBorella, CBossi, ESteidl, CScollo, CMologni, LPiazza, RGambacorti Passerini, C +
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 01 - Articolo su rivista 2023 Civettini, IvanZappaterra, AriannaGranelli, Bianca MariaRindone, GiovanniAroldi, AndreaBonfanti, StefanoColombo, FedericaFedele, MarilenaPerfetti, PaolaTerruzzi, ElisabettaGambacorti-Passerini, CarloRamazzotti, DanieleCavalca, Fabrizio +
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 01 - Articolo su rivista 2023 Fontana, DCrespiatico, ICrippa, VMalighetti, FVilla, MAngaroni, FAroldi, AAntoniotti, MCaravagna, GPiazza, RGraudenzi, AMologni, LRamazzotti, D +
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 01 - Articolo su rivista 2022 Gambacorti-Passerini, CarloAroldi, AndreaFontana, DilettaPiazza, RoccoAntolini, Laura +
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 01 - Articolo su rivista 2022 Bossi, ElisaAroldi, AndreaBorin, Lorenza MariaVerga, LuisaFontana, DilettaCocito, FedericaManghisi, BeatriceRindone, GiovanniCavalca, FabrizioRipamonti, AlessiaAntolini, LauraPiazza, Rocco GiovanniGambacorti-Passerini, Carlo +
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 01 - Articolo su rivista 2022 Inzoli E.Aroldi A.Piazza R.Gambacorti Passerini C.
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 01 - Articolo su rivista 2022 Steidl, CarolinaAroldi, AndreaMologni, LucaCrespiatico, IlariaFontana, DilettaMastini, CristinaBorin, LorenzaPiazza, RoccoGambacorti-Passerini, Carlo +
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 01 - Articolo su rivista 2021 Aroldi, AGambacorti Passerini, C +
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 01 - Articolo su rivista 2021 Gambacorti Passerini C.Aroldi A.Piazza R. +
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2020 Fontana, DilettaRamazzotti, DanieleAroldi, AndreaRedaelli, SaraMagistroni, VeraPirola, AlessandraMassimino, LucaMastini, CristinaBrambilla, VirginiaBombelli, SilviaElli, Elena MariaFumagalli, MonicaPerego, Roberto APagni, FabioMologni, LucaPiazza, RoccoGambacorti-Passerini, Carlo +
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 01 - Articolo su rivista 2020 Bossi E.Aroldi A.Steidl C.Verga L.Fontana D.Sharma G. G.Mologni L.Piazza R.Gambacorti Passerini C. +
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 01 - Articolo su rivista 2019 Aroldi A.Gambacorti-Passerini C.Antolini L. +
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 02 - Intervento a convegno 2019 Diletta FontanaDaniele RamazzottiAndrea AroldiLuca MassiminoElena Maria ElliMonica FumagalliRocco PiazzaCarlo Gambacorti-Passerini +
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 01 - Articolo su rivista 2019 Elli E.Aroldi A. +
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 01 - Articolo su rivista 2018 Aroldi, AndreaPioltelli, PietroGambacorti-Passerini, Carlo +
Chronic myeloid leukemia: Second-line drugs of choice 01 - Articolo su rivista 2016 GAMBACORTI PASSERINI, CARLOAroldi, ACORDANI, NICOLETTAPIAZZA, ROCCO GIOVANNI